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What is personalized medicine? In an 
ideal world, our vision for personalized 
medicine involves measurement of some 
key tumor characteristics which inform 
the optimum therapy regimen tailored 
for each given patient to successfully treat 
their cancer and prevent relapse. In reality, 
things are not so simple. Cancer is enor-
mously complex and heterogeneous and 
the current gaps in our knowledge preclude 
this vision from becoming a reality in the 
very near future. On the upside, ground-
breaking advancements in technology and 
approaches in recent years have enabled 
tremendous strides in this direction, but 
we have a long way to go if this vision is to 
be fully realized.
Where it all started
In 1942, at Yale School of Medicine, 
two pharmacologists, Louis Goodman 
and Alfred Gilman, injected the first 
patient, a Polish immigrant metal worker 
known only by the initials JD who had 
advanced lymphoma and a large mandibu-
lar tumor, with a classified experimental 
substance designated as ‘substance X’ in 
his medical records. Over the following 
weeks, they observed substantial tumor 
regression. Substance X was actually 
nitrogen mustard, a derivative of mustard 
gas discovered through chemical warfare 
research [1]. It worked by binding to the 
DNA of dividing cells resulting in cell 
death. This experiment was the first time 
a drug had been used to treat cancer and 
represented the beginnings of what we now 
call chemotherapy.
the beginnings of personalized 
medicine
The development and refinement of chem-
otherapy since then has revolutionized the 
treatment of cancer. Despite this, a large 
number of patients fail to respond to pri-
mary treatment or recur some time later, 
with the development of resistant malig-
nancies. Thus the need for a personalized 
medicine approach was realized by the sci-
entific community, in a move away from 
the ‘one-treatment-fits-all’ mindset [2,3]. To 
this day, breast cancer remains the most 
common cancer throughout the world, the 
most studied and best understood and will 
be the focus of this article exploring the 
concept of personalized medicine.
One of the most important discoveries 
in the field of cancer research was the estro-
gen receptor (ER) in breast cancer. While 
the dependence of breast cancers on the 
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hormone estrogen has been well established for at 
least 100 years, the ER itself was only identified 
in 1958 by Elwood Jensen [4]. 20 years later, the 
first commercial endocrine therapy, tamoxifen, 
was available. It blocked the action of this recep-
tor, revolutionizing the treatment of hormone-
dependent breast cancers with significantly less 
toxicity than its experimental predecessors. Prior 
to endocrine therapy, cessation of estrogen as a 
breast cancer treatment was achieved by ovarian 
oblation, as demonstrated by George Beatson in 
1896. However, not all women gained noticeable 
benefit [5]. Discovery of the ER eventually led 
to the first molecular test for breast cancer [6]. 
For the first time, benefit from therapy could 
be predicted to some degree of accuracy; those 
women with detectable ER in diagnosis biopsies 
would gain benefit from endocrine therapy and 
those without would not. Indeed, to this day ER 
remains the most widely used marker of endo-
crine therapy benefit in breast cancer. Despite 
this, while it has a high negative predictive value, 
with virtually all ER-negative patients gaining 
no benefit from endocrine therapy, around 
30–50% of those patients who are ER-positive 
will develop primary resistance or recur while on 
adjuvant therapy to prevent relapse [7].
the dawn of the genomic age
The latter part of the 20th century heralded 
the dawn of the genomic age. High-throughput 
technologies such as gene-expression microar-
rays gave researchers the opportunity to explore 
the underlying genetics of cancer with a high 
degree of detail and accuracy. In an effort to 
move toward a personalized approach, much 
work has been done to identify groups of patients 
with similar molecular characteristics which 
have significant associations with survival or 
drug response. In breast cancer, the pioneering 
work was done in 2001 by Sørlie, who, using 
gene-expression microarray technology, identi-
fied five distinct molecular subgroups of breast 
cancer with significantly different traits and 
survival associations [8]. The ER-positive pop-
ulation was subdivided into luminal A and B, 
the latter having significantly worse prognosis, 
and the ER-negative population was divided 
into basal, normal-like and HER2. The latter 
group expressed a cell surface receptor protein 
known as HER2, originally discovered in the 
1980s, which became the target of the drug 
Herceptin® [9,10]. Now testing for HER2 is 
included alongside ER (and another hormone 
receptor, progesterone receptor [PR]) as part of 
the routine diagnosis of breast cancer, and is the 
basis for prescription of Herceptin.
Since the initial work of Sørlie, the breast can-
cer molecular subtypes have been refined and 
redefined several times [11–14]. The increased 
accessibility of gene-expression microarrays and 
related high-throughput technologies, availabil-
ity and use of public data repositories and the 
development of new bioinformatics approaches 
have all fueled the ever-expanding plethora of 
high-throughput genomic experiments. The 
majority of these have been concerned with pro-
filing patients into groups with similar molecular 
characteristics associated with clinical end points 
such as prognosis or drug response. While this 
wealth of knowledge and data has revealed much 
about the underlying biology of cancer develop-
ment, evolution and drug resistance, to date very 
few of these studies have been translated to the 
clinical setting to directly impact the manage-
ment of breast cancer patients above and beyond 
the three markers (ER, PR and HER2) which 
are routinely used.
Only four prognostic/diagnostic tests for 
breast cancer currently have approval from 
the NICE for use in the UK, two of which, 
Oncotype DX® [15] and MammaPrint® [16], 
stemmed from large-scale genomic experiments. 
A third, IHC4 [17], uses immunohistochemistry 
(IHC) scoring of the three classic markers (ER, 
PR and HER2) plus Ki-67 and clinicopathologi-
cal variables to estimate risk while the fourth, 
Mammostrat® [18], uses IHC measurement of 
five unique markers (SLC7A5, HTF9C, P53, 
NDRG1 and CEACAM5). All four tests seek 
to identify subsets of patients with such a good 
prognosis, where the absolute benefit is small 
compared with the associated toxicity, that they 
could forgo adjuvant systemic chemotherapy. 
However, there are a number of limitations 
associated with these tests. First, Oncotype 
DX, MammaPrint and Mammostrat are costly, 
at around US$2000–4000 per patient and they 
require processing of tumor biopsy material in 
a central laboratory in the USA, which requires 
shipping of samples and can delay results by up 
to 10 days. All four tests have only been shown 
to have value in the ER-positive population of 
patients with no (or very few) positive lymph 
nodes and all four report results as a risk score 
subdivided into low-, medium- and high-risk 
groups, where the optimum clinical  management 
of medium-risk patients remains unclear.
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Selecting patients for therapy
The emergence of next-generation sequenc-
ing (NGS), with vastly improved throughput, 
speed, scalability and resolution, has ignited 
a revolution in genomic science allowing 
researchers to delve deeper into the genome, 
transcriptome and epigenome. While tests 
such as Oncotype DX and MammaPrint offer 
clinicians an important opportunity to make 
more effective use of systemic chemotherapy, 
the complexity and heterogeneity of cancer, 
now more apparent than ever before, has both 
highlighted the need and fueled the search for 
more targeted anticancer drugs.
Following on from Herceptin in 1998, we 
have seen a dramatic increase in the develop-
ment of companion diagnostic tests in parallel 
with development of new targeted anticancer 
drugs. These tests detect particular characteris-
tics of a cancer, such as specific proteins, tran-
scripts or mutations, thereby selecting patients 
who are likely to gain benefit or not from the 
associated therapy. Targeted drug development 
of this type has not only increased the clini-
cal success of new medications, by selecting 
specific subpopulations of patients where a 
given drug will be most effective, but has also 
afforded clinicians the first real opportunity to 
provide personalized care. As of July 2015, the 
US FDA has approved 18 companion diagnos-
tic tests for use with specific anticancer drugs 
and this number will grow over the coming 
years. Indeed, multiple companion diagnostic 
tests can be approved for a single drug, as is 
now the case for Herceptin. This continued 
development and improvement of such tests 
is essential as the scientific knowledge evolves 
allowing for increased sensitivity and speci-
ficity. When we consider that ER, the most 
commonly used diagnostic test for endocrine 
therapy in breast cancer, has a sensitivity of 
only around 50–70%, we can clearly appreciate 
the need for a more sophisticated test which 
can reliably and accurately predict response 
to therapy. Two tests which seek to do this, 
EndoPredict [19] and EndoResponse4 [20], not 
yet approved for clinical use, are currently in 
development.
Making the most of targeted therapy
Another important lesson from the laboratory 
has come from the study of cancer evolution, 
which has been aided significantly by deep 
sequencing technologies such as NGS. Recent 
studies have reported high numbers of hetero-
geneous gain and loss mutations which can 
occur between primary and distant sites and 
within primary tumors which develop drug 
resistance, drastically altering the biology of the 
cancer [21,22]. Based on these findings it seems 
clear that for optimal personalized care there is a 
need for clinicians, where possible, to take repeat 
biopsies of resistant tumors or biopsies of dis-
tant metastatic sites when considering targeted 
therapies. In many cases the cancer biology will 
have substantially changed and treatment deci-
sions made on baseline diagnostic biopsies may 
no longer be effective. Indeed, in terms of pre-
dicting drug response, one recent study demon-
strated the added value of an early on-treatment 
biopsy over baseline alone in predicting response 
to endocrine therapy, as the expression changes 
of some genes on therapy were more informative 
than their initial levels [20]. That said, while the 
anatomical location of breast tumors allows for 
routine biopsies to be easily performed under 
local anesthetic, this is not possible for some 
other cancers and distant metastatic sites. In 
time, improvements in blood testing including 
the isolation and analysis of circulating tumor 
cells may allow such tests to be performed 
noninvasively [23].
the future
Recent years have seen researchers and clini-
cians alike take great strides toward personal-
ized cancer care. The advent and use of new 
high-throughput technologies has resulted in 
a data explosion in the field of cancer research. 
The challenge over the coming years will be to 
bridge the gap between the bench and bedside. 
Our goal should be to translate the findings of 
these large-scale studies back to the clinic to 
directly improve patient care through identifica-
tion of new drug targets and continually devel-
oping and refining prognostic and diagnostic 
tests to determine which patients will benefit 
from which therapies. As the field of transla-
tional medicine continues to expand and new 
targeted therapies and their associated tests 
become available, these will have to be inte-
grated into the clinical care pathway to give 
clinicians the tools they need to make the most 
effective treatment decisions for each patient.
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